Digital biomarkers for Alzheimer's disease: the mobile/ wearable devices opportunity
- PMID: 31119198
- PMCID: PMC6526279
- DOI: 10.1038/s41746-019-0084-2
Digital biomarkers for Alzheimer's disease: the mobile/ wearable devices opportunity
Abstract
Alzheimer's Disease (AD) represents a major and rapidly growing burden to the healthcare ecosystem. A growing body of evidence indicates that cognitive, behavioral, sensory, and motor changes may precede clinical manifestations of AD by several years. Existing tests designed to diagnose neurodegenerative diseases, while well-validated, are often less effective in detecting deviations from normal cognitive decline trajectory in the earliest stages of the disease. In the quest for gold standards for AD assessment, there is a growing interest in the identification of readily accessible digital biomarkers, which harness advances in consumer grade mobile and wearable technologies. Topics examined include a review of existing early clinical manifestations of AD and a path to the respective sensor and mobile/wearable device usage to acquire domain-centric data towards objective, high frequency and passive digital phenotyping.
Conflict of interest statement
Competing interests: L.C.K., O.B.R., and J.G.W. have been employees at Eli Lilly and Company when part of this work was created. L.C.K. is currently a consultant to Evidation Health. The remaining authors declare no competing interests.
Figures
References
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
